Medication-induced exacerbation of neuropathy in Charcot Marie Tooth disease

被引:61
作者
Weimer, LH
Podwall, D
机构
[1] Columbia Univ Coll Phys & Surg, Dept Neurol, Inst Neurol, New York, NY 10032 USA
[2] Albert Einstein Coll Med, Neurol Associates Long Isl, New York, NY 10021 USA
关键词
toxic neuropathy; vincristine; chemotherapy; nucleoside analogs; hereditary neuropathy; drug-induced neuropathy;
D O I
10.1016/j.jns.2005.11.014
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Toxin or medication-induced worsening of preexisting peripheral neuropathy is a generally accepted but not well-studied phenomenon in humans. Drug-induced exacerbation of Charcot Marie Tooth disease (CMT) neuropathy is a common concern; a list of potential drugs to avoid is maintained by the CMT Association but with limited direct evidence or advice on relative risk. An extensive literature search for reported cases of drug effects in CMT patients found the vast majority concerned excessive vincristine toxicity in patients with undiagnosed demyelinating forms of CMT, many after I or 2 doses. The CMT North American database was also queried for all drug-related effects. All but one drug cited as worsening neuropathy was present on a compiled inclusive list. These results and other available evidence were used to develop a revised risk stratified list for CMT patients and clinicians to consult prior to discussing risk to benefit ratios and making treatment decisions. (c) 2005 Elsevier B.V. All rights reserved.
引用
收藏
页码:47 / 54
页数:8
相关论文
共 36 条
[1]   Peripheral neuropathy in patients treated with leflunomide [J].
Bonnel, RA ;
Graham, DJ .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (06) :580-585
[2]   Toxic neuropathy in patients with pre-existing neuropathy [J].
Chaudhry, V ;
Chaudhry, M ;
Crawford, TO ;
Simmons-O'Brien, E ;
Griffin, JW .
NEUROLOGY, 2003, 60 (02) :337-340
[3]   VINCRISTINE NEUROTOXICITY [J].
CHAUNCEY, TR ;
SHOWEL, JL ;
FOX, JH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1985, 254 (04) :507-507
[4]   Vincristine-induced neuropathy as the initial presentation of charcot-Marie-tooth disease in acute lymphoblastic leukemia: A pediatric oncology group study [J].
Chauvenet, AR ;
Shashi, V ;
Selsky, C ;
Morgan, E ;
Kurtzberg, J ;
Bell, B .
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (04) :316-320
[5]   Uneventful administration of cisplatin to a man with X-linked Charcot-Marie-Tooth disease (CMT) [J].
Cowie, F ;
Barrett, A .
ANNALS OF ONCOLOGY, 2001, 12 (03) :422-422
[6]   SEVERE VINCRISTINE NEUROTOXICITY IN A PATIENT WITH CHARCOT-MARIE-TOOTH DISEASE [J].
DICKERHOFF, R ;
LINDNER, W ;
SCHEIBER, W .
PEDIATRIC HEMATOLOGY AND ONCOLOGY, 1988, 5 (01) :61-64
[7]   Effects of antiretroviral therapy in patients with Charcot-Marie-Tooth disease type 1A [J].
Fernández-Torre, JL ;
García-Alcalde, M ;
Alvarez, V .
JOURNAL OF NEUROLOGY, 2002, 249 (07) :940-941
[8]   Statins and risk of polyneuropathy -: A case-control study [J].
Gaist, D ;
Jeppesen, U ;
Andersen, M ;
Rodríguez, LAG ;
Hallas, J ;
Sindrup, SH .
NEUROLOGY, 2002, 58 (09) :1333-1337
[9]  
GENY C, 1990, ANN MED INTERNE, V141, P709
[10]  
Graf WD, 1996, CANCER, V77, P1356, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1356::AID-CNCR20>3.3.CO